VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
| Autor: | Oaknin, A., Gladieff, L., Martinez-Garcia, J., Villacampa, G., Takekuma, M., De Giorgi, U.F.F., Lindemann, K., Woelber, L., Colombo, N., Duska, L.R., Leary, A., Godoy Ortiz, A., Nishio, S., Angelergues, A., Rubio Perez, M.J., Fariñas Madrid, L., Yamaguchi, S., Lorusso, D., D'Hondt, V., Randall, L. |
|---|---|
| Zdroj: | In Annals of Oncology December 2023 34(12):1198-1200 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|